Literature DB >> 10691911

Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC).

K J Palmer1, M Harries, M E Gore, M K Collins.   

Abstract

IFN-alpha administration after primary tumour resection improves the survival of melanoma patients at high risk of relapse. To investigate whether this response might be due to stimulation of anti-tumour immunity, the effect of IFN-alpha on anti-melanoma CTL generation in MLTC was measured. IFN-alpha increased both allogeneic and autologous anti-melanoma CTL generation from peripheral blood lymphocytes stimulated with irradiated primary melanoma cultures. IFN-alpha up-regulated MHC class I expression on primary melanoma cultures, whereas IFN-gamma up-regulated both MHC class I and II expression. However, the effect of IFN-alpha on anti-melanoma CTL generation was often more potent than that of IFN-gamma, equalling the effect of the optimal combination of IL-2 and IL-12. Pre-treatment of primary melanoma cultures with IFN-gamma was sufficient for CTL generation in MLTC, whereas IFN-alpha needed to be present during the MLTC. While direct anti-proliferative effects of IFN-alpha on some tumour cells have been described, IFN-alpha did not inhibit proliferation of primary melanoma cultures. These results suggest that the clinical effects of IFN-alpha in melanoma patients may be immune-mediated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691911      PMCID: PMC1905588          DOI: 10.1046/j.1365-2249.2000.01159.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Differential regulation of HLA-A3 and HLA-B7 MHC class I genes by IFN is due to two nucleotide differences in their IFN response sequences.

Authors:  R Hakem; P Le Bouteiller; A Jezo-Bremond; K Harper; D Campese; F A Lemonnier
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

2.  Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons.

Authors:  P Giacomini; R Gambari; R Barbieri; P Nisticò; R Tecce; S Pestka; K Gustafsson; P G Natali; P B Fisher
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480

3.  Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells.

Authors:  P Nisticò; R Tecce; P Giacomini; A Cavallari; I D'Agnano; P B Fisher; P G Natali
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

4.  Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients.

Authors:  P Giacomini; R Fraioli; A M Calabrò; F Di Filippo; P G Natali
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

5.  Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells.

Authors:  P G Coulie; M Somville; F Lehmann; P Hainaut; F Brasseur; R Devos; T Boon
Journal:  Int J Cancer       Date:  1992-01-21       Impact factor: 7.396

6.  Regulation of MHC expression in vivo. II. IFN-alpha/beta inducers and recombinant IFN-alpha modulate MHC antigen expression in mouse tissues.

Authors:  P F Halloran; J Urmson; P H Van der Meide; P Autenried
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

7.  Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells.

Authors:  V Brinkmann; T Geiger; S Alkan; C H Heusser
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

8.  Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression. Interactions with immune gamma interferon differentiate the effects of tumor necrosis factor and lymphotoxin from those of leukocyte alpha and fibroblast beta interferons.

Authors:  L A Lapierre; W Fiers; J S Pober
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

9.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

Authors:  B Van den Eynde; B Lethé; A Van Pel; E De Plaen; T Boon
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

10.  Control of H-2 expression in transformed nonhaemopoietic cells by autocrine interferon.

Authors:  P Nanni; L Landuzzi; G Nicoletti; C De Giovanni; M Giovarelli; E Lalli; A Facchini; P L Lollini
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more
  15 in total

1.  E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.

Authors:  Ahmad A Tarhini; Sandra J Lee; Xiaoxue Li; Uma N M Rao; Arun Nagarajan; Mark R Albertini; Jerry W Mitchell; Stuart J Wong; Mark A Taylor; Noel Laudi; Phu V Truong; Robert M Conry; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2018-11-12       Impact factor: 12.531

2.  Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

Authors:  Ahmad A Tarhini; John Cherian; Stergios J Moschos; Hussein A Tawbi; Yongli Shuai; William E Gooding; Cindy Sander; John M Kirkwood
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

Review 3.  Immune checkpoint blockade and interferon-α in melanoma.

Authors:  Imran Rafique; John M Kirkwood; Ahmad A Tarhini
Journal:  Semin Oncol       Date:  2015-02-14       Impact factor: 4.929

Review 4.  IFN-α in the treatment of melanoma.

Authors:  Ahmad A Tarhini; Helen Gogas; John M Kirkwood
Journal:  J Immunol       Date:  2012-10-15       Impact factor: 5.422

5.  Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.

Authors:  Rafael Carretero; José M Romero; Francisco Ruiz-Cabello; Isabel Maleno; Felix Rodriguez; Francisco M Camacho; Luis M Real; Federico Garrido; Teresa Cabrera
Journal:  Immunogenetics       Date:  2008-06-11       Impact factor: 2.846

6.  Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.

Authors:  Clay L Efferson; Jeanne Schickli; Byung Kyum Ko; Kouichiro Kawano; Sara Mouzi; Peter Palese; Adolfo García-Sastre; Constantin G Ioannides
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.

Authors:  Alexandra Garancher; Hiromichi Suzuki; Svasti Haricharan; Lianne Q Chau; Meher Beigi Masihi; Jessica M Rusert; Paula S Norris; Florent Carrette; Megan M Romero; Sorana A Morrissy; Patryk Skowron; Florence M G Cavalli; Hamza Farooq; Vijay Ramaswamy; Steven J M Jones; Richard A Moore; Andrew J Mungall; Yussanne Ma; Nina Thiessen; Yisu Li; Alaide Morcavallo; Lin Qi; Mari Kogiso; Yuchen Du; Patricia Baxter; Jacob J Henderson; John R Crawford; Michael L Levy; James M Olson; Yoon-Jae Cho; Aniruddha J Deshpande; Xiao-Nan Li; Louis Chesler; Marco A Marra; Harald Wajant; Oren J Becher; Linda M Bradley; Carl F Ware; Michael D Taylor; Robert J Wechsler-Reya
Journal:  Nat Neurosci       Date:  2020-05-18       Impact factor: 24.884

8.  A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.

Authors:  Andrew S Brohl; Nikhil I Khushalani; Zeynep Eroglu; Joseph Markowitz; Ram Thapa; Y Ann Chen; Ragini Kudchadkar; Jeffrey S Weber
Journal:  J Immunother Cancer       Date:  2016-12-20       Impact factor: 13.751

Review 9.  Type I interferons: key players in normal skin and select cutaneous malignancies.

Authors:  Aimen Ismail; Nabiha Yusuf
Journal:  Dermatol Res Pract       Date:  2014-01-05

Review 10.  The use of immunotherapy in the treatment of melanoma.

Authors:  Tala Achkar; Ahmad A Tarhini
Journal:  J Hematol Oncol       Date:  2017-04-24       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.